Welcome to our dedicated page for Neubase Therapeutics news (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on Neubase Therapeutics stock.
Neubase Therapeutics Inc (NASDAQ: NBSE) is a biotechnology innovator focused on developing precision therapies for rare genetic disorders through its modular antisense platform. This page serves as the definitive source for all company announcements, research milestones, and financial updates.
Investors and researchers can access timely updates on clinical trial progress, strategic partnerships, and scientific advancements in gene silencing technology. Our curated news provides transparent insights into NBSE's efforts to address conditions like Huntington's disease through targeted genetic solutions.
Key content includes earnings reports, regulatory filings, technology patents, and collaboration announcements. Each update is verified for accuracy to support informed decision-making in genetic medicine.
Bookmark this page for direct access to Neubase's official communications. Check regularly for new insights into one of biotechnology's most promising approaches to treating inherited disorders.
NeuBase Therapeutics (NASDAQ: NBSE) announced CEO Dietrich A. Stephan will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 11:20 a.m. ET. Both events will be held virtually with webcasts available on the company’s website. NeuBase focuses on innovative synthetic medicines to address genetic diseases, emphasizing its proprietary PATrOL™ therapies aimed at altering gene function to treat various disorders.
NeuBase Therapeutics (Nasdaq: NBSE) showcased significant advancements in gene therapy, particularly in treating myotonic dystrophy type 1 (DM1). The company validated its PATrOL™ platform, achieving successful outcomes in animal models. NeuBase plans to progress one program into clinical development by 2022 and is acquiring gene-modulating technology to enhance its offerings. Financially, NeuBase reported a net loss of $4.1 million for Q1 FY2021, an improvement from a $4.5 million loss in the same period last year. As of December 31, 2020, cash reserves stood at $28 million.
NeuBase Therapeutics (NBSE) announced the acquisition of peptide nucleic acid (PNA) technology from Vera Therapeutics, enhancing its PATrOL™ platform. This deal consolidates validated technology and intellectual property aimed at correcting malfunctioning genes to address various diseases, including cancers. The acquisition is positioned to accelerate NeuBase’s pipeline in genetic medicine. Financial terms were not disclosed, yet the transaction is expected to close in Q1 2021.
NeuBase Therapeutics (NASDAQ: NBSE) announced that CEO Dietrich A. Stephan, Ph.D., will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. The on-demand presentation will be available starting January 11 at 6:00 a.m. ET and can be accessed on NeuBase's website. NeuBase is focused on accelerating the genetic revolution with its synthetic medicines aimed at treating genetic diseases through its proprietary PATrOL™ therapies, targeting neurological, neuromuscular, and oncologic disorders.
NeuBase Therapeutics (Nasdaq: NBSE) has reported financial results for the fiscal year ended September 30, 2020, highlighting a net loss reduction from $26.1 million to $17.4 million. Cash and equivalents increased to approximately $32 million, ensuring funding into Q1 2022. The company announced positive preclinical data for its DM1 program, new management appointments, and plans for a new headquarters in Pittsburgh to support its PATrOL™ platform. An investor R&D day is expected in the first half of 2021 to provide further updates.
Dietrich A. Stephan, Ph.D., CEO of NeuBase Therapeutics (NASDAQ:NBSE), will present a webinar titled "Accelerating the Genetic Revolution with a New Class of Synthetic Medicines" on December 22, 2020, at 8:30 a.m. PDT. The free event, hosted by Tribe Public, includes a Q&A session. NeuBase focuses on innovative synthetic medicines targeting genetic diseases. Dr. Stephan is a pioneer in precision medicine, with extensive experience and contributions to the field. For registration, visit NeuBase22.TribePublic.com.
NeuBase Therapeutics (Nasdaq: NBSE) announced positive preclinical data for its PATrOL-enabled anti-gene therapies targeting myotonic dystrophy type 1 (DM1). The findings demonstrate that Compound A successfully resolves mis-splicing without affecting DMPK protein levels, supporting its mechanism of action. In vitro results showed significant correction of mis-spliced transcripts, while in vivo data from animal models confirmed effective engagement with target mRNA. NeuBase plans to discuss these advancements in a conference call on December 16, 2020.
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) has appointed Dr. Curt Bradshaw as its new Chief Scientific Officer. Dr. Bradshaw, previously with Arrowhead Pharmaceuticals, brings extensive experience in developing genetic medicines, particularly in RNA therapeutics. He will lead NeuBase's PATrOL-enabled anti-gene pipeline, advancing therapies for both rare and common diseases. The company is focused on redefining nucleic acid therapeutics, targeting disease-causing mutations to improve patient outcomes. Dr. Bradshaw's leadership is expected to positively influence NeuBase's growth trajectory.
NeuBase Therapeutics (NASDAQ: NBSE) announces participation in two significant events from December 1-3, 2020. Dietrich A. Stephan, Ph.D., CEO, will engage in a virtual fireside chat at the Piper Sandler Virtual Healthcare Conference and a panel discussion at the Evercore ISI HealthCONx Conference. A webcast of the fireside chat will be available on the Piper Sandler site and NeuBase's website for 90 days post-event. NeuBase focuses on advancing genetic therapies to tackle debilitating diseases using its innovative PATrOL™ technologies.
NeuBase Therapeutics (Nasdaq: NBSE) announced the appointment of Eriks Rozners, Ph.D. and Randy Davis, MBA, to its scientific advisory board. Dr. Rozners, an expert in nucleic acid biochemistry, and Mr. Davis, a biotechnology veteran, are expected to enhance the company's research and development efforts. Their diverse expertise will support NeuBase's PATrOL platform, which aims to provide innovative treatments for genetic disorders. NeuBase focuses on silencing mutations in various medical fields aimed at redefining genetic medicine.
